SG11202104875XA - Immunogenic peptides with improved oxidoreductase motifs - Google Patents
Immunogenic peptides with improved oxidoreductase motifsInfo
- Publication number
- SG11202104875XA SG11202104875XA SG11202104875XA SG11202104875XA SG11202104875XA SG 11202104875X A SG11202104875X A SG 11202104875XA SG 11202104875X A SG11202104875X A SG 11202104875XA SG 11202104875X A SG11202104875X A SG 11202104875XA SG 11202104875X A SG11202104875X A SG 11202104875XA
- Authority
- SG
- Singapore
- Prior art keywords
- immunogenic peptides
- improved
- oxidoreductase motifs
- motifs
- improved oxidoreductase
- Prior art date
Links
- 102000004316 Oxidoreductases Human genes 0.000 title 1
- 108090000854 Oxidoreductases Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18205615 | 2018-11-12 | ||
| EP18205611 | 2018-11-12 | ||
| PCT/EP2019/080929 WO2020099356A2 (en) | 2018-11-12 | 2019-11-12 | Immunogenic peptides with improved oxidoreductase motifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104875XA true SG11202104875XA (en) | 2021-06-29 |
Family
ID=68655497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104875XA SG11202104875XA (en) | 2018-11-12 | 2019-11-12 | Immunogenic peptides with improved oxidoreductase motifs |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20210401976A1 (en) |
| EP (2) | EP3880237A2 (en) |
| JP (2) | JP2022513019A (en) |
| KR (1) | KR20210093933A (en) |
| CN (2) | CN113015542A (en) |
| AU (2) | AU2019379760A1 (en) |
| BR (1) | BR112021009210A2 (en) |
| CA (2) | CA3118981A1 (en) |
| CO (1) | CO2021007060A2 (en) |
| CU (1) | CU20210041A7 (en) |
| IL (1) | IL282849A (en) |
| MX (1) | MX2021005540A (en) |
| PE (1) | PE20211494A1 (en) |
| PH (1) | PH12021551101A1 (en) |
| SG (1) | SG11202104875XA (en) |
| TW (1) | TW202043255A (en) |
| WO (2) | WO2020099352A2 (en) |
| ZA (1) | ZA202102909B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2657480T3 (en) | 2006-08-11 | 2018-03-05 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| BR112019018616A2 (en) * | 2017-03-09 | 2020-04-28 | Imcyse Sa | peptides and methods for treating diabetes |
| CN115916805A (en) * | 2020-05-06 | 2023-04-04 | 易姆赛斯股份公司 | Immunogenic peptides with extended oxidoreductase motifs |
| CA3181635A1 (en) * | 2020-05-06 | 2021-11-11 | Imcyse Sa | Immunogenic peptides with new oxidoreductase motifs |
| EP4346883A1 (en) | 2021-05-26 | 2024-04-10 | Imcyse SA | Methods of treating or preventing autoimmune diseases |
| AR126654A1 (en) * | 2021-06-29 | 2023-11-01 | Imcyse Sa | PEPTIDES AND METHODS FOR THE TREATMENT OF OPTICAL NEUROMYELITIS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004520803A (en) * | 2000-04-21 | 2004-07-15 | コリクサ コーポレイション | Compositions and methods for the treatment and diagnosis of acne vulgaris |
| EP1501922A4 (en) * | 2001-12-21 | 2005-07-27 | Univ Rochester | Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions |
| EP1523557A2 (en) * | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
| ES2657480T3 (en) * | 2006-08-11 | 2018-03-05 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| PL2249864T3 (en) | 2008-02-14 | 2016-11-30 | Strategies to prevent and/or treat immune responses to soluble allofactors | |
| CA2715536C (en) | 2008-02-14 | 2018-01-16 | Life Sciences Research Partners Vzw | Cd4+ t-cells with cytolytic properties |
| EP2106803A1 (en) * | 2008-04-04 | 2009-10-07 | Fondazione Centro San Raffaele del Monte Tabor | Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients |
| DE11787873T1 (en) * | 2010-11-25 | 2013-12-12 | Imnate Sarl | Immune peptides for use in the prevention and / or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejections and immune responses to viral vectors |
| GB201309469D0 (en) * | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| RU2018136760A (en) * | 2016-04-19 | 2020-05-19 | Имсис Са | NEW IMMUNOGENIC CD1d-BINDING PEPTIDES |
-
2018
- 2018-11-12 US US17/292,893 patent/US20210401976A1/en active Pending
-
2019
- 2019-11-12 SG SG11202104875XA patent/SG11202104875XA/en unknown
- 2019-11-12 EP EP19797967.7A patent/EP3880237A2/en active Pending
- 2019-11-12 WO PCT/EP2019/080925 patent/WO2020099352A2/en unknown
- 2019-11-12 JP JP2021525806A patent/JP2022513019A/en active Pending
- 2019-11-12 BR BR112021009210-2A patent/BR112021009210A2/en unknown
- 2019-11-12 AU AU2019379760A patent/AU2019379760A1/en active Pending
- 2019-11-12 CN CN201980074481.1A patent/CN113015542A/en active Pending
- 2019-11-12 PE PE2021000701A patent/PE20211494A1/en unknown
- 2019-11-12 TW TW108141034A patent/TW202043255A/en unknown
- 2019-11-12 AU AU2019377983A patent/AU2019377983A1/en active Pending
- 2019-11-12 KR KR1020217017332A patent/KR20210093933A/en active Search and Examination
- 2019-11-12 CA CA3118981A patent/CA3118981A1/en active Pending
- 2019-11-12 CU CU2021000041A patent/CU20210041A7/en unknown
- 2019-11-12 CA CA3118620A patent/CA3118620A1/en active Pending
- 2019-11-12 US US17/292,888 patent/US20220288179A1/en active Pending
- 2019-11-12 CN CN201980074437.0A patent/CN113015541A/en active Pending
- 2019-11-12 WO PCT/EP2019/080929 patent/WO2020099356A2/en unknown
- 2019-11-12 EP EP19797966.9A patent/EP3880236A2/en active Pending
- 2019-11-12 JP JP2021525809A patent/JP2022513021A/en active Pending
- 2019-11-12 MX MX2021005540A patent/MX2021005540A/en unknown
-
2021
- 2021-04-30 ZA ZA2021/02909A patent/ZA202102909B/en unknown
- 2021-05-02 IL IL282849A patent/IL282849A/en unknown
- 2021-05-12 PH PH12021551101A patent/PH12021551101A1/en unknown
- 2021-05-28 CO CONC2021/0007060A patent/CO2021007060A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20210041A7 (en) | 2021-12-08 |
| WO2020099356A3 (en) | 2020-07-23 |
| CN113015541A (en) | 2021-06-22 |
| US20220288179A1 (en) | 2022-09-15 |
| CA3118981A1 (en) | 2020-05-22 |
| WO2020099352A2 (en) | 2020-05-22 |
| EP3880237A2 (en) | 2021-09-22 |
| JP2022513021A (en) | 2022-02-07 |
| CO2021007060A2 (en) | 2021-06-10 |
| PH12021551101A1 (en) | 2021-12-13 |
| WO2020099352A3 (en) | 2020-07-09 |
| WO2020099356A2 (en) | 2020-05-22 |
| EP3880236A2 (en) | 2021-09-22 |
| JP2022513019A (en) | 2022-02-07 |
| ZA202102909B (en) | 2022-09-28 |
| MX2021005540A (en) | 2021-06-18 |
| PE20211494A1 (en) | 2021-08-11 |
| IL282849A (en) | 2021-06-30 |
| US20210401976A1 (en) | 2021-12-30 |
| CA3118620A1 (en) | 2020-05-22 |
| BR112021009210A2 (en) | 2021-08-10 |
| TW202043255A (en) | 2020-12-01 |
| KR20210093933A (en) | 2021-07-28 |
| AU2019377983A1 (en) | 2021-05-27 |
| CN113015542A (en) | 2021-06-22 |
| AU2019379760A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282849A (en) | Immunogenic peptides with improved oxidoreductase motifs | |
| IL268920A (en) | Peptide vaccines | |
| EP3119424A4 (en) | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof | |
| SG11202010821TA (en) | Vaccine composition | |
| EP3385286A4 (en) | Vaccine antigen with increased immunogenicity | |
| IL265805A (en) | Immunogenic arginase peptides | |
| GB201802339D0 (en) | Immunogenic composition | |
| GB201711635D0 (en) | Immunogenic composition | |
| GB201711637D0 (en) | Immunogenic composition | |
| EP4076504A4 (en) | Modified interferon-alpha-2 having reduced immunogenicity | |
| IL281224A (en) | Peptide vaccines | |
| GB201910794D0 (en) | Vaccine | |
| IL282753A (en) | Immunogenic composition | |
| IL278830A (en) | Reverse peptide vaccine | |
| EP3741388A4 (en) | Immunogenic composition | |
| IL284006A (en) | Mitochondria-targeting peptides | |
| IL271404A (en) | Improved protein expression strains | |
| EP3595696A4 (en) | Immunogenic peptide composition | |
| GB201803692D0 (en) | Immunogenic composition | |
| GB201811382D0 (en) | Vaccine | |
| EP3706787A4 (en) | Vaccine | |
| EP3677276A4 (en) | Vaccine composition | |
| GB201820010D0 (en) | Immunogenic composition | |
| GB201911636D0 (en) | Vaccine | |
| IL289717A (en) | Antibodies with reduced immunogenicity |